Pittman Scott M. 4
4 · Nuo Therapeutics, Inc. · Filed Jan 26, 2026
Research Summary
AI-generated summary of this filing
Nuo Therapeutics (AURX) 10% Owner Scott M. Pittman Receives Award
What Happened
Scott M. Pittman, a 10% owner of Nuo Therapeutics (AURX), was granted derivative awards on January 23, 2026 totaling 74,316 shares at an exercise/acquisition price of $1.50 per share (aggregate value $111,474). The grants are derivative in nature (warrants/shares issuable upon certain events) and were approved as part of a Loan and Security Agreement dated January 21, 2026 that the board and non-employee directors approved.
Key Details
- Transaction date: January 23, 2026; filing date: January 26, 2026.
- Instruments and amounts: six derivative grants totaling 74,316 shares at $1.50 each (total = $111,474). Individual tranches: 2,050; 1,333; 26,667; 1,750; 35,000; 7,516 shares.
- Nature: Derivative awards/warrants or shares issuable under the Loan Agreement (not an open-market purchase).
- Vesting/vesting conditions (footnotes):
- Some awards vest (if at all) on Sept 30, 2026 only if a “Second Funding” occurs per the Loan Agreement (F1).
- Some awards vest upon a Prepayment event but no later than Dec 31, 2028 (F2).
- One footnote (F3) shows the maximum shares issuable on Prepayment.
- Shares owned after transaction: not specified in the filing.
- Filing timeliness: report filed Jan 26, 2026 covering the Jan 23, 2026 transaction; the filing does not indicate a late-report code.
Context
These are contingent/derivative awards tied to a financing arrangement (Loan Agreement) rather than a straightforward cash purchase or sale. For retail investors, such grants reflect compensation/consideration related to financing terms and may only convert into common shares if specified funding or prepayment events occur. As a 10% owner, Pittman is a significant shareholder; this transaction is part of corporate financing mechanics rather than routine open-market buying or selling.
Insider Transaction Report
- Award
Commitment Warrants (right to buy)
2026-01-23$1.50/sh+2,050$3,075→ 0 totalExercise: $1.50From: 2026-01-23Exp: 2031-01-23→ Common Stock (2,050 underlying) - Award
Origination Initial Warrants (right to buy)
2026-01-23$1.50/sh+1,333$2,000→ 0 totalExercise: $1.50From: 2026-01-23Exp: 2031-01-23→ Common Stock (1,333 underlying) - Award
Capital Initial Warrants (right to buy)
2026-01-23$1.50/sh+26,667$40,001→ 0 totalExercise: $1.50From: 2026-01-23Exp: 2031-01-23→ Common Stock (26,667 underlying) - Award
Origination Second Warrants (right to buy)
[F1]2026-01-23$1.50/sh+1,750$2,625→ 0 totalExercise: $1.50From: 2026-09-30Exp: 2031-01-23→ Common Stock (1,750 underlying) - Award
Capital Second Warrants (right to buy)
[F1]2026-01-23$1.50/sh+35,000$52,500→ 0 totalExercise: $1.50From: 2026-09-30Exp: 2031-01-23→ Common Stock (35,000 underlying) - Award
Prepayment Warrants (right to buy)
[F2][F3]2026-01-23$1.50/sh+7,516$11,274→ 0 totalExercise: $1.50From: 2026-01-23Exp: 2031-01-23→ Common Stock (7,516 underlying)
Footnotes (3)
- [F1]Will vest (if at all) on September 30, 2026 provided a Second Funding occurs in accordance with the Loan and Security Agreement dated January 21, 2026 among the Issuer, the Reporting Person, and other parties thereto (the "Loan Agreement").
- [F2]Will vest (if at all) upon the occurrence of a Prepayment, but no later than December 31, 2028, in accordance with the Loan Agreement.
- [F3]Represents maximum number of shares issuable (if at all) in the event of a Prepayment in accordance with the Loan Agreement. The Board of Directors of Issuer and Non-Employee Directors approved the Loan Agreement and issuance of warrants and shares of Common Stock issuable thereunder